Management of Discoid Lupus Erythematosus

First-Line Treatment Approach

The American College of Rheumatology recommends hydroxychloroquine 200-400 mg daily as the cornerstone of systemic therapy for discoid lupus erythematosus, combined with strict photoprotection and potent topical corticosteroids for localized lesions 1, 2
Strict sun avoidance and comprehensive photoprotective measures are mandatory for all patients, as ultraviolet exposure directly induces and exacerbates discoid lesions 3
Potent topical corticosteroids, such as fluocinonide 0.05% cream, are the mainstay of initial treatment for localized cutaneous manifestations 2

Hydroxychloroquine is recommended for all patients with discoid lupus unless contraindicated, with dosing at 200 mg once daily or 400 mg daily, not exceeding 5 mg/kg actual body weight to minimize retinal toxicity risk 2
Mandatory ophthalmological screening is required, with baseline examination, repeat after 5 years, then yearly thereafter 2

Methotrexate is effective for various cutaneous manifestations, particularly with predominant articular involvement 4, 2
Mycophenolate mofetil demonstrates efficacy for refractory cutaneous disease 2
Retinoids, such as acitretin, are useful for hyperkeratotic and hypertrophic lesions, with comparable efficacy to hydroxychloroquine but more frequent/severe adverse effects 2
Dapsone is particularly effective for bullous lupus and urticarial vasculitis presentations 2

For widespread or severe disease, short-term systemic glucocorticoids should be added to expedite control 2
Chronic maintenance goal is to minimize glucocorticoids to less than 7.5 mg/day prednisone equivalent and withdraw when possible 4, 2

Regular evaluation of number and type of skin lesions using validated activity indices, such as BILAG or SLEDAI, is recommended 5, 2
Laboratory monitoring, including complete blood count, renal function, complement levels, and anti-dsDNA antibodies, should be performed every 6-12 months when inactive, and more frequently during active disease or medication adjustments 5, 1, 3
Immunological markers, such as anti-dsDNA, anti-Ro/SSA, anti-La/SSB, and antiphospholipid antibodies, provide prognostic information for systemic involvement 5, 3

Pregnancy considerations: hydroxychloroquine is safe during pregnancy, but methotrexate, mycophenolate mofetil, and thalidomide are contraindicated 4, 2
Infection surveillance: maintain high index of suspicion as immunosuppression increases infection risk 1, 2